Bill banning AI therapy bots in Illinois awaits signature

SPRINGFIELD, Ill. (WCIA) — Illinois could soon require humans to be in charge of all therapy sessions.
The Illinois Legislature passed a bill to the governor's desk that would ban the use of therapy offered by Artificial Intelligence. Mental health professionals would also only be able to use AI transcriptions of sessions if the patient consents to it.
Illinois bill ending scam gym membership tactic heads to governor's desk
The National Association for Social Workers said while artificial intelligence could be a promising tool in the future, right now it is not bound by ethics.
'These AI chat bots, even though you can try to program as best as you can, they're not human,' said Kyle Hillman, the legislative director for NASW-IL. 'They don't have that interaction they don't have that kind of response. And so, they're influenced by what kind of data comes into those products and that influence is changing the biases towards, I think, dangerous conservations.'
Durbin pushes to pass DACA bill ahead of 13th anniversary
The bill's House sponsor said guardrails need to be set in stone before technology advances too far.
'Our behavioral healthcare system cannot afford to be replaced by unqualified chatbots with no malpractice liability,' Rep. Bob Morgan (D-Deerfield) said in a news release. 'By explicitly laying out what AI technology can and cannot be used for, patients are better protected, providers can continue delivering critical access to care, and treatment plans remain transparent between the client and professional.'
If signed into law, Illinois would be the first state to ban these chatbots.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Fox News

4 days ago

• Fox News

Obama swipes at affluent liberals during rare public remarks, says 'all of us are going to be tested'

Former President Barack Obama took aim at affluent liberals on Tuesday, saying they would be "tested in some way," unlike during his presidency, warning the crowd they would have to decide what their priorities would be. The former Democratic president said during remarks in Hartford, Connecticut that liberals "felt comfortable in their righteousness" during his presidency because it wasn't challenged. "You could be as progressive and socially conscious as you wanted, and you did not have to pay a price," he said. Obama offered no direct rebukes to current events while conversing with historian Heather Cox Richardson, according to The New York Times, only issuing veiled criticisms of President Donald Trump during his remarks. He didn't mention the president by name once. "You could still make a lot of money. You could still hang out in Aspen and Milan and travel and have a house in the Hamptons and still think of yourself as a progressive," Obama said, according to the Times. "We now have a situation in which all of us are going to be tested in some way, and we are going to have to decide what our commitments will be." "Now things are a little different," he said. "You might lose some of your donors if you're a university and if you're a law firm, your billings might drop a little bit, which means you cannot remodel that kitchen in your house in the Hamptons this summer." The Times reported that Obama urged businesses, law firms, and universities to counter Trump's policies. The former president posted on X about immigration on Sunday, suggesting immigrants were "being demonized and treated as enemies" in the U.S. "Thirteen years ago, my administration acted to protect young people who were American in every single way but one: on paper," the Democrat said in a social media post. "DACA was an example of how we can be a nation of immigrants and a nation of laws. And it's an example worth remembering today, when families with similar backgrounds who just want to live, work, and support their communities, are being demonized and treated as enemies," the former president said, referring to Deferred Action for Childhood Arrivals. The Atlantic reported on June 8 that some progressives have been frustrated by the former president's lack of more vocal opposition to Trump. "There are many grandmas and Rachel Maddow viewers who have been more vocal in this moment than Barack Obama has," co-founder of the Progressive Change Institute, Adam Green, told the Atlantic. "It is heartbreaking," Green said, "to see him sacrificing that megaphone when nobody else quite has it."

Business Wire

5 days ago

• Business Wire

ICD 2025: New data demonstrate Nemluvio ® 's (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data show Nemluvio is well tolerated and associated with sustained and clinically meaningful improvements in symptoms including itch and skin lesions, during prolonged treatment up to two years. 1 These new data will be presented as a late-breaking session at ICD, on Saturday, June 21, 2025 at 08:30 AM CET. Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules, which have a substantial impact on patients' quality of life. 5-7 Nemluvio is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. 8,9,10 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation, skin barrier dysfunction, and fibrosis in prurigo nodularis. 8-11 It is also the first and only biologic approved for prurigo nodularis as well as atopic dermatitis with four-week dosing intervals from the start of treatment. 9,10 The OLYMPIA long-term extension study was designed to assess the safety and efficacy of Nemluvio in patients with prurigo nodularis up to four years and includes 508 patients from the phase II trial or the phase III OLYMPIA 1 and 2 trials. 1 Results show that treatment with Nemluvio is associated with sustained and clinically meaningful improvements in symptoms of prurigo nodularis during prolonged treatment up to two years. 1 At Week 100 in evaluable patients, the interim analysis shows that: More than 90% and 70% achieved at least a four-point improvement in itch, and being itch free or nearly itch free respectively, as measured by the Peak-Pruritus Numerical Rating Scale 1 At least 80% achieved 76‑100% healed pruriginous lesions 1 Approximately 75% reached clearance or almost-clearance of skin nodules when assessed using the Investigator's Global Assessment score 1 Nemluvio was well tolerated in the long-term treatment of prurigo nodularis and no new safety signals were identified in this study to date. 1 'These impressive results give us even more confidence in the value of nemolizumab – a much-needed innovative medicine that has the potential to deeply impact the prurigo nodularis treatment landscape. With this new treatment now approved in multiple markets including the EU and U.S., I'm thrilled to be able to see its meaningful impact in the real world.' PROF. SONJA STÄNDER Expand This follows presentation of results from the ARCADIA long-term extension study at the RAD Conference earlier this month, which showed that treatment with Nemluvio was well tolerated and associated with sustained and increased improvements in symptoms of atopic dermatitis during prolonged treatment up to two years. 4 Nemluvio was first approved in August 2024 by the United States Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis. 9 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. 9 To date, Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including the European Commission. Additional reviews and submissions are ongoing. Galderma will also host a symposium at ICD, exploring the latest advances in addressing itch in both prurigo nodularis and atopic dermatitis. Separately, the company will share new data from across its Therapeutic Dermatology portfolio in acne, non-melanoma skin cancer, and rosacea. More details on Galderma's scientific presentations at ICD can be found here. About Nemluvio Nemluvio was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga ® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients. 12,13 About prurigo nodularis Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas. 5-7 It is an underrecognized and underdiagnosed skin condition, and there are limited studies investigating its prevalence. 11,14,15 About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: References Ständer S, et a. Nemolizumab long-term efficacy and safety up to 100 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: An interim analysis. Presented at International Congress of Dermatology; June 18-21, 2025; Rome, Italy. A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501679). Available online. Accessed May 2025 Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501666). Available online. Accessed May 2025 Silverberg, JI, et al. Nemolizumab long-term safety and efficacy up to 104 weeks in the ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis. Presented at Revolutionizing Atopic Dermatitis Conference 2025; June 6-7; Nashville, United States. Huang AH, et al. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565. doi: 10.1016/ Pereira MP, et al. European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059-1065. doi: 10.1111/jdv.14570 Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42. doi: 10.1097/itx.0000000000000042 Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182. doi: 10.1016/ Nemluvio U.S. Prescribing Information. Available online. Accessed May 2025 Nemluvio European Medicines Agency. Summary of Product Characteristics. Available online. Accessed May 2025 Bewley A, et al. Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments. Dermatol Ther (Heidelb). 2022;12(9):2039–2048. doi: 10.1007/s13555-022-00782-2 Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed May 2025 Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed May 2025 Ständer S, et al. Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis. JAAD Int. 2020;2:28-30. doi: 10.1016/ Huang AH, et al. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol.

Black America Web

5 days ago

• Black America Web

DACA Turns 13 In Uncertain Times, As Obama Voices Support

Source: Win McNamee / Getty The 13th anniversary of the DACA program is celebrated as it faces uncertainty under the Trump Administration. On Sunday (June 15), the Deferred Action for Childhood Arrivals (DACA) program celebrated 13 years of existence after its creation during the administration of former President Barack Obama. It comes as the administration of President Donald Trump has endorsed numerous raids by Immigration and Customs Enforcement (ICE) agents nationwide, and has worked to end the program outright, doing so for six months in his first term. In a post on X, formerly Twitter, Obama honored the day and the program, which was created to provide a pathway to aid the young children of immigrants to becoming citizens and to protect them from deportation. 'Thirteen years ago, my administration acted to protect young people who were American in every single way but one: on paper,' the former president began in the post. 'DACA was an example of how we can be a nation of immigrants and a nation of laws. And it's an example worth remembering today, when families with similar backgrounds who just want to live, work, and support their communities, are being demonized and treated as enemies.' Obama concluded, 'We can fix our broken immigration system while still recognizing our common humanity and treating each other with dignity and respect. In fact, it's the only way we ever will.' Obama was joined by a slew of other Democratic lawmakers voicing their own support for DACA on social media, and who called for the passage of the bipartisan H.R. 1589 bill, commonly referred to as the 'American Dream and Promise Act'. The bill, if passed by both the House of Representatives and the Senate, would codify parts of DACA into federal law. The 5th Circuit Court ruled against DACA being continued in full in January, but allowed applications for renewal to continue. The Trump Administration recently received a verdict in its favor from the Supreme Court, 7-2, to remove Temporary Protected Status from over 500,000 immigrants from Cuba, Haiti, Nicaragua and Venezuela last month drawing ire from advocates. DACA and the issue of protecting young immigrants have taken center stage again within the past week, as protesters decrying the deportations and policies of ICE outside of a federal building in downtown Los Angeles were confronted by local police. President Donald Trump moved to send in 2,000 members of the National Guard, and subsequently 200 Marines without approval from California Governor Gavin Newsom or Los Angeles Mayor Karen Bass. DACA Turns 13 In Uncertain Times, As Obama Voices Support was originally published on Black America Web Featured Video CLOSE